New Delhi: GV Prasad has been reappointed as the Co-Chairman and Managing Director of Dr Reddy’s Laboratories for an additional five-year term, which would keep him in that position until 29 January 2031.
The company’s shareholders must approve this reappointment at the next Annual General Meeting, but it has been in effect since 30 January 2026, according to the Board of Directors.
Dr Reddy’s development and international recognition have been greatly influenced by GV Prasad. His leadership is distinguished by a strong dedication to promoting an innovative and research-oriented culture, which propels the creation of novel and easily accessible medications.
Under his direction, the business has strengthened its emphasis on openness and moral business practices, solidifying its standing as a reliable healthcare partner across the globe.
In addition to his primary duties at Dr Reddy’s, GV Prasad is an active member of the academic and business communities. He is affiliated with the McKinsey Centre for CEO Excellence and holds prestigious positions at the Indian School of Business (ISB), where he is a member of the Governing Board.
GV Prasad’s reappointment signifies stability and consistency for Dr Reddy’s Laboratories as it aims to expand and innovate in the future. Stakeholders hope that his ongoing direction will further solidify the business’s dedication to providing high-quality medications and having a significant influence on healthcare around the world.
Given Prasad’s stellar record and broad esteem among investors and the industry, the impending shareholder ratification is anticipated to be a formality. His longer term ensures a sustained emphasis.
Also Read –
Neo Group Bolsters Leadership Team with Shajikumar Devakar Appointment
